Study wrapper · #340
Safety Profile of Bremelanotide Across the Clinical Development Program.
Editor's note
This is a safety review pooling bremelanotide's (PT-141) entire clinical development program — about 3,500 subjects across 43 studies, with Phase 3 exposure up to 18 months — making it the most complete adverse-event picture available for the compound. The signal is clear and worth foregrounding: nausea affected 40% versus 1.3% on placebo and was the leading reason for discontinuation; flushing (20%), headache (11%) and injection-site reactions were also elevated. Focal skin hyperpigmentation, driven by the same MC1R activity as tanning peptides, was rare at the labeled on-demand dose but appeared in over a third of subjects with daily dosing — a caution against frequent off-label use. Small, transient blood-pressure rises were measured, and the authors advise caution in those at cardiovascular risk. No deaths occurred. As a manufacturer-adjacent review it is not adversarial, but the AE data are specific and quantified. Consult this for tolerability, not efficacy.
Plain-language abstract
This review gathers the safety data from bremelanotide's (PT-141) full testing program — about 3,500 people across 43 studies, some taking the drug for up to 18 months. In the main Phase 3 trials (1,247 people), the most common side effects compared with placebo were nausea (40% vs about 1%), flushing (20%), headache (11%), and reactions at the injection site. Nausea was the most common reason people stopped taking it. There were no deaths, and only a few people had serious side effects. Darkening of patches of skin (hyperpigmentation) was uncommon when the drug was used as directed (occasionally, before sexual activity), but happened in more than a third of people who took it daily for up to 16 days in a row. Monitoring showed small, temporary rises in blood pressure. The authors say side effects were mostly mild to moderate but advise caution in people at risk of heart disease, and note that blood pressure should be well controlled during use. Two drug interactions were flagged, lowering blood levels of indomethacin and naltrexone.